Skip to main content

Diabetes

  • J&J submits new FDA application for Nucynta ER

    TITUSVILLE, N.J. — A Johnson & Johnson subsidiary has sent a regulatory application to the Food and Drug Administration seeking approval for one of its drugs in treating diabetes-related pain.

  • Walgreens offers free testing during National Diabetes Month

    DEERFIELD, Ill. — Select Walgreens across the country will offer free blood-glucose testing during National Diabetes Month this November, Walgreens announced Monday.

  • Affordable Care Act ensures women receive preventive services at no additional cost

    WASHINGTON — New guidelines that will ensure women receive preventive health services at no additional cost were announced Monday by the Department of Health and Human Services.

    Developed by the independent Institute of Medicine, the new guidelines require new health insurance plans to cover women’s preventive services, such as well-woman visits, breast-feeding support, domestic violence screening and contraception without charging a co-payment, co-insurance or a deductible.

  • Lilly, Lupin enter diabetes partnership

    NEW DELHI — Eli Lilly’s India division and Indian generic drug maker Lupin will distribute Lilly’s insulin products in India and Nepal under an agreement between the two companies announced Friday.

    Under the collaboration, Lilly and Lupin will promote and distribute Huminsulin R, Huminsulin NPH, Huminsulin 50/50, Huminsulin 30/70 and Humapen Ergo II. The companies said the deal would double the current customer base.

  • Fourth annual Retail Clinician Education Congress brings together retail healthcare professionals

    ORLANDO, Fla. — This year’s fourth annual Retail Clinician Education Congress kicked off on Monday, bringing together hundreds of retail healthcare professionals to network, receive exclusive accreditation and honor those providers and key executive leaders whose work throughout the year has distinguished them among their peers in retail health care.

  • Strides Arcolab's generic diabetes drug enters market

    BANGALORE, India — The Food and Drug Administration has approved a generic drug for diabetes made by Indian generic drug maker Strides Arcolab.

    The FDA approved acarbose tablets in the 25-mg, 50-mg and 100-mg strengths. The drug is a niche drug used to treat Type 2 diabetes, Strides said.

    Acarbose tablets have sales of about $21 million, according to IMS Health.

  • Bydureon reply submitted to FDA

    INDIANAPOLIS — Drug makers Eli Lilly, Amylin Pharmaceuticals and Alkermes are giving their long-acting form of an injected drug for Type 2 diabetes another try at the Food and Drug Administration.

  • Publix to offer free diabetes screenings at more than 800 locations

    LAKELAND, Fla. — Publix will offer free diabetes screenings at more than 800 Publix stores this year, the grocer announced Wednesday.

X
This ad will auto-close in 10 seconds